STE Steris
Q4 2025 10-Q
Filed: Feb 6, 2026Period ending Dec 31, 2025
Health Care
Orthopedic, Prosthetic & Surgical Appliances & SuppliesSEC EDGAR Steris (STE) 10-Q quarterly report for Q4 2025, filed with SEC EDGAR on Feb 6, 2026 for the fiscal period ending Dec 31, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
AI Filing AnalysisQ4 2025 10-Q
Management Discussion & Analysis
- • Revenue $1,496.2M Q3 FY2026, up 9.2% YoY from $1,370.6M; nine months revenue $4,347.5M, up 9.3% from $3,979.0M
- • Operating margin Q3 FY2026 18.2% ($273.2M/$1,496.2M) vs 17.9% YoY ($245.3M/$1,370.6M); nine months margin 18.1% vs 16.3% YoY
Risk Factors
- • No new or updated risk factors reported since the fiscal 2025 10-K filed May 29, 2025
- • Continued risks from product liability and regulatory compliance remain material, including FDA regulations on medical devices
Quarterly Financial SummaryXBRL
Revenue
$1.5B
▲ +9.2% YoY▲ +2.5% QoQ
Net Income
$193M
▲ +11.2% YoY▲ +0.6% QoQ
Net Margin
12.9%
▲ +23bp YoY▼ -24bp QoQ
Source: XBRL data from Steris Q4 2025 10-Q filing on SEC EDGAR. All figures in USD.
Other Steris Quarterly Reports
Get deeper insights on Steris
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.